MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue Bank

Summary

The purposes of this study are: 1. To identify and quantify the health utilities and quality of life experienced by patients who have been diagnosed with MDS and what are their predictors. 2. Measure the effects of patient related factors like frailty and comorbidity on quality of life and overall survival or toxicity to therapy. 3. Assess how quality of life changes over time and what are its predictors. This will be valuable information that may guide therapy, transfusion practices, etc., as MDS is a chronic, incurable disease that is often progressive.

Conditions

• Myelodysplastic Syndrome (MDS)

Sponsors & Collaborators

• Tom Baker Cancer Centre

  collaborator OTHER

• CancerCare Manitoba

  collaborator OTHER

• The Ottawa Hospital

  collaborator OTHER

• Princess Margaret Hospital, Canada

  collaborator OTHER

• Jewish General Hospital

  collaborator OTHER

• Health Sciences Centre, Winnipeg, Manitoba

  collaborator OTHER

• British Columbia Cancer Agency

  collaborator OTHER

• Providence Health & Services

  collaborator OTHER

• Vancouver Coastal Health

  collaborator OTHER_GOV

• Juravinski Cancer Center

  collaborator OTHER

• Réseau de Santé Vitalité Health Network

  collaborator OTHER

• Royal Victoria Hospital, Canada

  collaborator OTHER

• Capital Health, Canada

  collaborator OTHER

• Saskatoon City Hospital

  collaborator OTHER

• Sunnybrook Health Sciences Centre

  lead OTHER

Principal Investigators

• Rena Buckstein, MD FRCPC · Sunnybrook Health Science Centre

Eligibility

Min Age

19 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2005-08-31

Primary Completion

2020-02-29

Completion

2020-02-29

Countries

• Canada

Study Locations